Clinical Radiology
Volume 63, Issue 7 , Pages 774-782 , July 2008

Diffusion-weighted magnetic resonance imaging: a potential non-invasive marker of tumour aggressiveness in localized prostate cancer

  • N.M. deSouza

      Affiliations

    • Institute of Cancer Research and Royal Marsden NHS Foundation Trust, UK
    • Corresponding Author InformationGuarantor and correspondent: N.M. deSouza, MRI Unit, Institute of Cancer Research and Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PT, UK. Tel.: +44 20 8661 3119/3289; fax: +44 20 8661 0846.
    • ,
  • S.F. Riches

      Affiliations

    • Institute of Cancer Research and Royal Marsden NHS Foundation Trust, UK
    • ,
  • N.J. VanAs

      Affiliations

    • Academic Urology Unit, Royal Marsden NHS Foundation Trust and Institute of Cancer Research, UK
    • ,
  • V.A. Morgan

      Affiliations

    • Institute of Cancer Research and Royal Marsden NHS Foundation Trust, UK
    • ,
  • S.A. Ashley

      Affiliations

    • Department of Computing, Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK
    • ,
  • C. Fisher

      Affiliations

    • Department of Histopathology, Royal Marsden NHS Foundation Trust and Institute of Cancer Research, UK
    • ,
  • G.S. Payne

      Affiliations

    • Institute of Cancer Research and Royal Marsden NHS Foundation Trust, UK
    • ,
  • C. Parker

      Affiliations

    • Academic Urology Unit, Royal Marsden NHS Foundation Trust and Institute of Cancer Research, UK

Received 20 November 2007 ,Revised 29 January 2008 ,Accepted 6 February 2008.

References 

  1. Bill-Axelson A, Holmberg L, Ruutu M, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med. 2005;352:1977–1984
  2. Albertsen PC, Hanley JA, Gleason DF, et al. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA. 1998;280:975–980
  3. Chism DB, Hanlon AL, Horwitz EM, et al. A comparison of the single and double factor high-risk models for risk assignment of prostate cancer treated with 3D conformal radiotherapy. Int J Radiat Oncol Biol Phys. 2004;59:380–385
  4. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280:969–974
  5. Zelefsky MJ, Lyass O, Fuks Z, et al. Predictors of improved outcome for patients with localized prostate cancer treated with neoadjuvant androgen ablation therapy and three-dimensional conformal radiotherapy. J Clin Oncol. 1998;16:3380–3385
  6. Partin AW, Mangold LA, Lamm DM, et al. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology. 2001;58:843–848
  7. Stephenson AJ, Scardino PT, Eastham JA, et al. Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst. 2006;98:715–717
  8. Casciani E, Polettini E, Bertini L, et al. Prostate cancer: evaluation with endorectal MR imaging and three-dimensional proton MR spectroscopic imaging. Radiol Med (Torino). 2004;108:530–541
  9. Kirkham AP, Emberton M, Allen C. How good is MRI at detecting and characterising cancer within the prostate?. Eur Urol. 2006;50:1163–1174
  10. Graser A, Heuck A, Sommer B, et al. Per-sextant localization and staging of prostate cancer: correlation of imaging findings with whole-mount step section histopathology. AJR Am J Roentgenol. 2007;188:84–90
  11. Dhingsa R, Qayyum A, Coakley FV, et al. Prostate cancer localization with endorectal MR imaging and MR spectroscopic imaging: effect of clinical data on reader accuracy. Radiology. 2004;230:215–220
  12. Futterer JJ, Scheenen TW, Heijmink SW, et al. Standardized threshold approach using three-dimensional proton magnetic resonance spectroscopic imaging in prostate cancer localization of the entire prostate. Invest Radiol. 2007;42:116–122
  13. Katz S, Rosen M. MR imaging and MR spectroscopy in prostate cancer management. Radiol Clin North Am. 2006;44:723–734viii
  14. Wang L, Hricak H, Kattan MW, et al. Prediction of organ-confined prostate cancer: incremental value of MR imaging and MR spectroscopic imaging to staging nomograms. Radiology. 2006;238:597–603
  15. Coakley FV, Qayyum A, Kurhanewicz J. Magnetic resonance imaging and spectroscopic imaging of prostate cancer. J Urol. 2003;170:S69–S76
  16. Zakian KL, Sircar K, Hricak H, et al. Correlation of proton MR spectroscopic imaging with gleason score based on step-section pathologic analysis after radical prostatectomy. Radiology. 2005;234:804–814
  17. Futterer JJ, Heijmink SW, Scheenen TW, et al. Prostate cancer localization with dynamic contrast-enhanced MR imaging and proton MR spectroscopic imaging. Radiology. 2006;241:449–458
  18. Girouin N, Mege-Lechevallier F, Tonina SA, et al. Prostate dynamic contrast-enhanced MRI with simple visual diagnostic criteria: is it reasonable?. Eur Radiol. 2007;17:1498–1509
  19. Jackson AS, Parker CC, Norman AR, et al. Tumour staging using magnetic resonance imaging in clinically localised prostate cancer: relationship to biochemical outcome after neo-adjuvant androgen deprivation and radical radiotherapy. Clin Oncol. 2005;17:167–171
  20. Beaulieu C, D'Arceuil H, Hedehus M, et al. Diffusion-weighted magnetic resonance imaging: theory and potential applications to child neurology. Semin Pediatr Neurol. 1999;6:87–100
  21. Provenzale JM, Sorensen AG. Diffusion-weighted MR imaging in acute stroke: theoretic considerations and clinical applications. AJR Am J Roentgenol. 1999;173:1459–1467
  22. Rowley HA, Grant PE, Roberts TP. Diffusion MR imaging. Theory and applications. Neuroimaging Clin N Am. 1999;9:343–361
  23. Sotak CH. New NMR measurements in epilepsy. Diffusion-weighted magnetic resonance imaging of spreading depression. Adv Neurol. 1999;79:925–929
  24. Chenevert TL, Stegman LD, Taylor JM, et al. Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors. J Natl Cancer Inst. 2000;92:2029–2036
  25. Galons JP, Altbach MI, Paine-Murrieta GD, et al. Early increases in breast tumor xenograft water mobility in response to paclitaxel therapy detected by non-invasive diffusion magnetic resonance imaging. Neoplasia. 1999;1:113–117
  26. Gibbs P, Tozer DJ, Liney GP, et al. Comparison of quantitative T2 mapping and diffusion-weighted imaging in the normal and pathologic prostate. Magn Reson Med. 2001;46:1054–1058
  27. Gupta RK, Cloughesy TF, Sinha U, et al. Relationships between choline magnetic resonance spectroscopy, apparent diffusion coefficient and quantitative histopathology in human glioma. J Neurooncol. 2000;50:215–226
  28. Maier CF, Paran Y, Bendel P, et al. Quantitative diffusion imaging in implanted human breast tumors. Magn Reson Med. 1997;37:576–581
  29. Shimofusa R, Fujimoto H, Akamata H, et al. Diffusion-weighted imaging of prostate cancer. J Comput Assist Tomogr. 2005;29:149–153
  30. Hayashida Y, Hirai T, Morishita S, et al. Diffusion-weighted imaging of metastatic brain tumors: comparison with histologic type and tumor cellularity. AJNR Am J Neuroradiol. 2006;27:1419–1425
  31. deSouza NM, Reinsberg SA, Scurr ED, et al. Magnetic resonance imaging in prostate cancer: value of apparent diffusion coefficients for identifying malignant nodules. Br J Radiol. 2007;80:90–95
  32. Akin O, Sala E, Moskowitz CS, et al. Transition zone prostate cancers: features, detection, localization, and staging at endorectal MR imaging. Radiology. 2006;239:784–792
  33. Valonen PK, Lehtimaki KK, Vaisanen TH, et al. Water diffusion in a rat glioma during ganciclovir–thymidine kinase gene therapy-induced programmed cell death in vivo: correlation with cell density. J Magn Reson Imaging. 2004;19:389–396
  34. Zhao D, Ran S, Constantinescu A, et al. Tumor oxygen dynamics: correlation of in vivo MRI with histological findings. Neoplasia. 2003;5:308–318
  35. Master VA, Chi T, Simko JP, et al. The independent impact of extended pattern biopsy on prostate cancer stage migration. J Urol. 2005;174:1789–1793
  36. Issa B. In vivo measurement of the apparent diffusion coefficient in normal and malignant prostatic tissues using echo-planar imaging. J Magn Reson Imaging. 2002;16:196–200
  37. Reinsberg SA, Payne GS, Riches SF, et al. Combined use of diffusion-weighted MRI and 1H MR spectroscopy to increase accuracy in prostate cancer detection. AJR Am J Roentgenol. 2007;188:91–98
  38. Miao H, Fukatsu H, Ishigaki T. Prostate cancer detection with 3-T MRI: comparison of diffusion-weighted and T2-weighted imaging. Eur J Radiol. 2007;61:297–302
  39. Kozlowski P, Chang SD, Jones EC, et al. Combined diffusion-weighted and dynamic contrast-enhanced MRI for prostate cancer diagnosis–correlation with biopsy and histopathology. J Magn Reson Imaging. 2006;24:108–113
  40. Nelson BA, Shappell SB, Chang SS, et al. Tumour volume is an independent predictor of prostate-specific antigen recurrence in patients undergoing radical prostatectomy for clinically localized prostate cancer. BJU Int. 2006;97:1169–1172
  41. Bettendorf O, Oberpenning F, Kopke T, et al. Implementation of a map in radical prostatectomy specimen allows visual estimation of tumor volume. Eur J Surg Oncol. 2007;33:352–357
  42. Ponchietti R, Di Loro F, Fanfani A, et al. Estimation of prostate cancer volume by endorectal coil magnetic resonance imaging vs. pathologic volume. Eur Urol. 1999;35:32–35
  43. Jager GJ, Ruijter ET, van de Kaa CA, et al. Local staging of prostate cancer with endorectal MR imaging: correlation with histopathology. AJR Am J Roentgenol. 1996;166:845–852
  44. Nakashima J, Tanimoto A, Imai Y, et al. Endorectal MRI for prediction of tumor site, tumor size, and local extension of prostate cancer. Urology. 2004;64:101–105

PII: S0009-9260(08)00082-2

doi: 10.1016/j.crad.2008.02.001

Clinical Radiology
Volume 63, Issue 7 , Pages 774-782 , July 2008

Article Tools

* Image Usage & Resolution